The combination of an ITK inhibitor and pembrolizumab was probed in other solid tumors, including mismatch repair proficient metastatic colorectal cancer (23), metastatic urothelial cancer (24), and advanced pancreatic cancer (25). This evidence concerns the gene ITK and metastatic colorectal cancer.